| 名稱 | ADCP Bioassay Effector Cell FcγRIIa (H variant)-NF | 
| 型號(hào) | CBP74106 | 
| 報(bào)價(jià) | ![]()  | 
								
| 特點(diǎn) | ADCP Bioassay Effector Cell FcγRIIa (H variant)-NFAT/Jurkat,母細(xì)胞:Jurkat,凍存條件:90% FBS+10% DMSO | 
產(chǎn)品搜索
相關(guān)文章
- 特應(yīng)性皮炎(AD)賽道新治療——OX40靶點(diǎn)
 - 降糖&減肥明星靶點(diǎn):GLP1R/GIPR/GCGR
 - 對(duì)ATCC細(xì)胞培養(yǎng)時(shí)的試劑有何要求?
 - 探討腫瘤細(xì)胞的“冷與熱”之分
 - HRD檢測(cè)之我見(jiàn)---科佰生物
 - IDH基因診斷標(biāo)準(zhǔn)品
 - sigma試劑的抗菌作用機(jī)制分析
 - 你見(jiàn)過(guò)低至6000元,還贈(zèng)對(duì)照的慢病毒包裝嗎?
 - 【產(chǎn)品推介】MSI標(biāo)準(zhǔn)品
 - 【靶點(diǎn)模型+診斷質(zhì)控】BCR-ABL1的藥物開(kāi)發(fā)和診斷
 
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
					產(chǎn)品展示  / PRODUCTS
					
						藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株  >  CBP74106ADCP Bioassay Effector Cell FcγRIIa (H variant)-NF
            
              
					
				
				
						- 詳細(xì)內(nèi)容
 
| I. Background | |
      ADCP(Antibody dependent cellular phagocytosis)是抗體依賴性細(xì)胞介導(dǎo)的吞噬作用。 是一種免疫消除機(jī)制,其憑借單克隆抗體(mAb)靶向腫瘤細(xì)胞,以促進(jìn)吞噬免疫細(xì)胞將 腫瘤細(xì)胞從體內(nèi)清除。ADCP 由單核細(xì)胞、巨噬細(xì)胞、嗜中性粒細(xì)胞和樹(shù)突細(xì)胞通過(guò)表達(dá) FcγRIIa(CD32a)、FcγRI(CD64)和 FcγRIIIa(CD16a)來(lái)介導(dǎo)來(lái)吞噬疾病細(xì)胞,研究表 明 FcγRIIa 是參與該過(guò)程的 FcγR 受體。  | |
| II. Description | |
      ADCP Bioassay Effector Cell FcγRIIa(H variant) -NFAT Jurkat 報(bào)告基因藥靶模型很好的 模擬了體內(nèi) ADCP 的信號(hào)轉(zhuǎn)導(dǎo)過(guò)程,原理見(jiàn)下圖所示。 
 Figure 1. ADCP Bioassay Effector Cell FcγRIIa(H variant) -NFAT Jurkat 細(xì)胞模型原理圖  | |
| III. Introduction | |
| Host Cell: | Jurkat | 
| Expressed gene: | FcγRIIa (H variant)-NFAT | 
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) | 
| Freeze Medium: | 90% FBS+10% DMSO | 
| Culture Medium: | RPMI-1640+10%FBS+1 μg/ml Puromycin+400 μg/ml Hygromycin B | 
| Storage: | Liquid nitrogen | 
| Application(s): | Functional(Report Gene) Assay | 
| IV. Description of Host Cell Line | |
| Organism: | Human | 
| Tissue: | Peripheral blood | 
| Disease: | Childhood T acute lymphoblastic leukemia | 
| Morphology: | Lymphoblast | 
| Growth Properties: | Suspension | 
| Ⅴ. Representative Data | |
 Figure 2. Dose Response of Rituximab in ADCP Bioassay Effector Cell FcγRlla (H variant) -NFAT Jurkat (C2) with Raji.  | |






會(huì)員_a.png)